Pipeline
The Science
About us
Investors
News

Hit enter to search or ESC to close

Prana Biotechnology Investor Presentation

June 27, 2018 Kerry Rowe

1_Prana Biotechnology Investor Presentation_2018-0627 final

Post navigation

Prana to commence Phase 1 clinical trial of PBT434 for treatment of parkinsonian diseases

First volunteers dosed in Phase I clinical trial of PBT434, Prana’s lead therapy for parkinsonian diseases

Related Posts

ATH434 protects brain cells and improves motor function

April 21, 2021June 23, 2021

Chairman’s Address to Shareholders 2019 Annual General Meeting

November 26, 2019November 26, 2019

The Lancet Neurology publishes Prana’s Huntington’s Disease Trial

November 18, 2014

Recent Posts

Presentation of New Biomarker Data at Scientific Congress
XBRL 30 June 2021 filed with the SEC
Alterity Announces New US Patent to Expand its Portfolio of Compounds for Neurodegenerative Diseases including Alzheimer’s and Parkinson’s
Quarterly Cash Flow Report
New Publication Demonstrates ATH434 is Neuroprotective

Recent Comments

Archives

Archives

Categories

ASX Announcements
Investor Announcement

About us

We exist to create an alternate future for people living with neurodegenerative diseases. An alternate, healthier life. We’re here to disrupt the trajectory the world has come to accept for people with these diseases.
Improving lives.

Pipeline
The Science
About us
Investors
News

Careers
Privacy Policy

Copyright © Alterity Therapeutics. ABN 37 080 699 065